Chairperson’s Perspective: HER2 in Solid Tumors – From Pathology to Personalized Treatment Plans
About this episode
Dr. Kathleen Moore discusses the clinical significance of HER2 in solid tumors and its implications for personalized treatment plans.
CME credits: 0.25 Valid until: 01-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-her2-in-solid-tumors-from-pathology-to-personalized-treatment-plans/54582/ Dr. Kathleen Moore reviews the clinical significance of HER2 expression across diverse solid tumors and its role in guiding treatment decisions. She outlines HER2 testing methodologies, including immunohistochemistry (IHC), to identify patients with advanced solid tumors who may benefit from HER2-targeted antibody–drug conjugates (ADCs). Dr. Moore summarizes key data from trials such as DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02 that supported tumor-agnostic approval of trastuzumab deruxtecan (T-DXd) for previously treated metastatic HER2-positive (IHC 3+) solid tumors, along with strategies for proactive monitoring and management of ADC-associated adverse events. =
People in this episode
Guest: Dr. Kathleen Moore
Mentioned in this episode
Organizations: HER2, DESTINY-PanTumor02, DESTINY-Lung01, DESTINY-CRC02
Products: trastuzumab deruxtecan (T-DXd)
More episodes of ReachMD CME
- No Patient With CKD Left Behind: New Horizons in Patients With CKD Regardless of Diabetes Status
- Closing the Gaps: Global Implementation of Lipid Guidelines
- Translating Evidence Into Action: Nonsteroidal MRAs in Patients With HF
- Unblocking Clinical Inertia: The CMI Era in oHCM Care
- Chairperson’s Perspective: Reframing First-Line and Subsequent Care in Advanced Urothelial Carcinoma – Clinical Implications of the Updated NCCN Guidelines
- Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Explore listener stats, chart rankings, contacts and more on the ReachMD CME podcast page.